THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024. "Strong growth in sales and earnings this quarter reflects the momentum we're building throughout our business. We continue to invest heavily in our rapidly advancing pipeline, with a focus on delivering innovative therapies across our core therapeutic areas," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the third quarter, total r ...

Core Insights - The article discusses the benefits of investing in dividend stocks, highlighting Visa and Amgen as strong candidates for long-term investment due to their business models and growth potential. Visa - Visa operates a leading payment processing network that connects merchants and banks, allowing for smooth transaction flows without credit risk as it does not issue cards or extend loans [2]. - The company earns fees from millions of daily transactions, benefiting from high gross and net margins due to low incremental operating costs for additional transactions [2][3]. - Visa enjoys a competitive advantage through network effects and a strong brand, making it difficult for competitors to gain market share [3][4]. - The company has significant growth potential as it captures a larger share of the global payments market, especially in developing countries where cash and check payments are still prevalent [4]. - Visa's dividends have increased by 333% over the past decade, with a forward yield of 0.7% and a cash payout ratio of just under 22%, indicating room for further dividend increases [5]. Amgen - Amgen is a leading drugmaker with a strong track record of innovation and a portfolio of over two dozen medicines, several generating more than $1 billion in annual sales [6]. - The company has expanded its product lineup through acquisitions, including the $28 billion purchase of Horizon Therapeutics, enhancing its portfolio with Tepezza, a therapy for thyroid eye disease [6][7]. - Amgen is actively developing new compounds, including a promising weight loss medicine called MariTide, supported by its financial resources and industry experience [7]. - The company reported a revenue increase of 40.51% and a net income increase of 30.22%, with a dividend growth of 268.9% [8]. - Amgen's forward yield is nearly 2.9%, with a cash payout ratio of 86%, reflecting its commitment to rewarding shareholders despite recent acquisitions [8].

THOUSAND OAKS, Calif., Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The dividend will be paid on December 9, 2024, to all stockholders of record as of the close of business on November 18, 2024. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there. I last covered Amgen (NASDAQ: AMGN ) for Seeking Alpha in early August, reviewing the California based Pharma giant's Q2 earnings. I gave its stock a "Buy" rating, however ...

Analysts on Wall Street project that Amgen (AMGN) will announce quarterly earnings of $5.11 per share in its forthcoming report, representing an increase of 3% year over year. Revenues are projected to reach $8.52 billion, increasing 23.4% from the same quarter last year. The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates duri ...

THOUSAND OAKS, Calif., Oct. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.Live audio of the conferenc ...

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on approved drugs and drug candidates in research and development as biosimilar antibodies of Prolia & Xgeva (denosumab).This product consists of: Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.Projec ...

Amgen (AMGN) will report third-quarter 2024 results on Oct. 30, after market close. In the last reported quarter, the company beat earnings expectations by 0.81%.The Zacks Consensus Estimate for sales and earnings is pegged at $8.51 billion and $5.11 per share, respectively.Factors to Consider for AmgenAmgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Prolia and Blincyto among others. However, prices of most products are expected to continue to ...

This biotech leader could be poised to rally higher.Amgen (AMGN -0.09%) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant and Dow Jones Industrial Average component, pending clinical-trial data from its drug pipeline has added a layer of uncertainty.On the other hand, the company continues to deliver strong growth with overall positive fundamentals. So is now a good time to pick up so ...

The latest trading session saw Amgen (AMGN) ending at $325.09, denoting a +0.14% adjustment from its last day's close. The stock's change was more than the S&P 500's daily loss of 0.76%. On the other hand, the Dow registered a loss of 0.75%, and the technology-centric Nasdaq decreased by 1.01%.Shares of the world's largest biotech drugmaker have depreciated by 3.17% over the course of the past month, outperforming the Medical sector's loss of 3.35% and lagging the S&P 500's gain of 4.31%.The investment comm ...